2 Gene-Editing Stocks to Have on Your Radar Right Now
Some companies that are leaders in gene editing get a lot of attention. CRISPR Therapeutics (NASDAQ: CRSP) and Intellia Therapeutics (NASDAQ: NTLA) especially stand out. Both have already reported promising data from early stage clinical studies evaluating their respective gene-editing therapies.
But there are also other biotechs that are making key advances in gene editing. While most of them not as widely followed as CRISPR Therapeutics and Intellia, they're worth watching. Here are two top gene-editing stocks to have on your radar right now.
Image source: Getty Images.
Source Fool.com
